Table 1.
Baseline characteristics of patients in the trials included in the meta-analysis
| Author | Study design | Treatment regimen | No of patients | Median age (year, range) | Male/female | Tumor location (femur/tibia/humerus/other) | Metastases (yes/no) | Jadad scale |
|---|---|---|---|---|---|---|---|---|
| Le Deley et al20 | RCT | MTX + ETO + IFO | 118 | 13.3 (5.5–19.3) | 72/46 | 55/27/11/25 | 0/118 | 3 |
| MTX + DOX | 116 | 13.2 (3.1–19.5) | 59/57 | 52/23/16/24 | 0/116 | |||
| Meyers et al21 | RCT | DOX + CDP + HDMTX | 677 | 13 (1–30) | 373/304* | 374/185/73/45* | 0/377 | 3 |
| DOX + IFO + HDMTX | 13 (1–30) | |||||||
| Bacci et al22 | RCT | HDMTX | 142 | 88/54 | 80/NR/NR/62 | 23/119 | 3 | |
| HDMTX + IFO | 79 | 42/37 | 50/NR/NR/0 | 6/73 | ||||
| Chou et al23 | RCT | CDP, DOX, MTX, IFO | 46 | 1–30 | 28/18 | 29/16/7/39* | 20/62* | 3 |
| CDP, DOX, MTX | 45 | 1–30 | 28/17 | |||||
| Meyers et al24 | RCT | CDP, DOX, MTX, IFO | 662* | 13 (1–30) | 361/301* | 364/184/72/42* | NR* | 3 |
| CDP, DOX, MTX | 13 (1–30) | |||||||
| Grier et al25 | RCT | VCR, CYC, DOX, IFO | 198 | NR | 120/78 | 35/19/16/127 | 0/198 | 3 |
| VCR, CYC, DOX | 200 | NR | 106/94 | 38/19/13/130 | 0/200 | |||
| Ferrari et al26 | RCT | MTX, CDP, DOX, IFO | 123 | 14 (6–39) | 74/49 | 62/34/14/13 | 0/123 | 4 |
| MTX, CDP, DOX | 123 | 14 (4–34) | 72/51 | 69/26/20/8 | 0/123 |
Note:
*
Data for all the patients.
Abbreviations: CDP, cisplatin; CYC, cyclophosphamide; DOX, doxorubicin; ETO, etoposide; HDMTX, high-dose methotrexate; IFO, ifosfamide; MTX, methotrexate; NR, not reported; RCT, randomized controlled trial; VCR, vincristine.